Back

Pharma

2nd Annual Microbiome: Translating into Diagnostics and Therapeutics Summit

  • 2nd – 3rd October 2018
  • Austria flag Austria Vienna
  • Hilton Garden Inn Vienna South Hertha-Firnberg-Straße 5, 1100

We are pleased to invite you to the 2nd Annual Microbiome: Translating into Diagnostics and Therapeutics Summit scheduled for October 2nd 3rd, 2018 in Vienna, Austria. This Summit is co-located with Immuno-Oncology & 4th Annual Biomarkers - CDx - Precision Immunotherapy Summits.

Read more

Co-located with Immuno-Oncology & Dx

The co-located Summits will bring together decision makers and industry leaders with both scientific and commercial interests to expand the scientific horizons of Biomarkers, Precision Medicine, Companion Dx, Immuno-Oncology and Microbiome, and will shed the light on the latest advancements and improvements in research and development, business opportunities in partnering, and investment. We will discuss key findings, critical insights, as well as recommendations for accelerating development in the field.

Who Should Attend

Chief Executives, Directors, Vice Presidents, Department Heads, Leaders, and Managers specialising in:

  • Microbiome/Microbiota
  • Microbiology
  • Computational biology
  • Autoimmune Disease
  • Infectious Diseases
  • Inflammation
  • Food/Nutrition Science
  • Genotyping
  • Biomarkers
  • Data Management
  • Metagenomics
  • High-Throughput Screening
  • Diagnostic & Clinical Applications
  • Licensing or Technology Transfer
  • Regulatory
  • Clinical trials
  • Bacteria / Fungi / Viruses
  • Molecular Biology
  • Molecular Diagnostics
  • Immuno-oncology
  • Metabolic Disease
  • Vaccines
  • Neurodegeneration / Gut-Brain Axis
  • Genomics
  • Bioinformatics
  • Epigenetics
  • NGS
  • Personalized / Targeted Therapeutics
  • Venture Capitalists
  • Business Development/In-Licensing
  • Market Access

Key Practical Learning Points

  • Emerging science and technologies for successful microbiome discovery and translation
  • Clinical applications of microbiome in oncology and beyond
  • Commercialisation and investment perspectives of microbiome – based diagnostics and therapeutics
  • Regulatory compliance for microbiome drugs
  • Translation of microbiome products:
  • Into clinical trials
  • For healthy nutrition
  • Into personalised therapeutics and diagnostic

Dr. Frédéric Baribaud, US

Scientific Director

Janssen R&D

About Speaker

Dr. Shahram Lavasani, SE

Founder & CEO

ImmuneBiotech AB

About Speaker

Dr. Barbara Joyce-Shaikh, US

Project Leader, Discovery Research

Merck Research Laboratories

About Speaker

Dr. Oliver Chao, FR

Head, Emerging Biomedical Sciences Strategy & Innovation

Sanofi

About Speaker

Dr. Bram Vanparys, NL

Partner – Health & Care

Gimv

About Speaker

Dr. Hassan Benameur, DE

Senior Director Oral Drug Delivery Innovation, Global Pharma Biotech R&D

Lonza Biologics plc

About Speaker

Dr. Olga Sakwinska, CH

Nestlé Institute of Health Sciences

Nestlé Research Center

About Speaker

Dr. Colette Shortt, UK

Former Director, Global Regulatory Affairs Emerging Science & Innovation J&J Consumer Health

J&J Consumer Health

About Speaker

Dr. Kristin Wannerberger, CH

Director Alliance Management R&D

Ferring Pharmaceuticals

About Speaker

Dr. Audrey Gueniche, FR

Clinical Scientific Coordinator / Senior Expert, Advanced Research

L’Oréal Research & Innovation

About Speaker

Dr. Jean de Gunzburg, UK

Chief Scientific Officer

Da Volterra

About Speaker

Dr. Gregory Lambert, FR

CEO – VP R&D

TargEDys SA

About Speaker

Dr. Patrice Garnier, FR

Chief Executive Officer

Amabiotics

About Speaker

Dr. Ylaine Gerardin, US

Data Scientist

Finch

About Speaker

Dr. Imke Mulder, UK

Research Director

4D Pharma Research Ltd.

About Speaker

Dr. Gianluca Ianiro, IT

Digestive Disease Center

IRCCS Fondazione Policlinico Universitario ‘A. Gemelli’, Rome

About Speaker

Dr. Morten L. Isaksen, NO

CEO

Bio-Me

About Speaker

Dr. Frédéric Baribaud, US

Scientific Director

Janssen R&D

Frédéric (Fred) Baribaud is a scientific director at Janssen R&D in the early development immunology biomarker department where he leads the rheumatology biomarker group. Fred has over 10 years work experience on personalized medicine approaches in several immunological diseases such as UC, CD, asthma, COPD, RA, Lupus, and PsO. His group’s work is focused on establishing pharmacodynamic assays, patient segmentation for response prediction, and characterize disease driving pathways. He joined Janssen R&D in 2006 after spending four years at Incyte Corporation in Wilmington working on target validation and co-leading SMI compound development teams. Prior to this, he was a post-doctoral fellow at the University of Pennsylvania working on HIV entry. Fred holds a BS and an MS in biochemistry from the University of Geneva, Switzerland and a PhD in biology from the University of Lausanne, Switzerland.

Dr. Shahram Lavasani, SE

Founder & CEO

ImmuneBiotech AB

Shahram Lavasani holds a Ph.D. degree from Lund University in Medical Inflammation Research where he studied the immunoregulation and novel immunotherapies in multiple sclerosis (MS). He has performed his post doc studies at Department of Surgery, University Hospital in Malmö, focusing on sepsis and lever injury. He is a skillful immunologist, with many years of teaching and research expertise on gastrointestinal complications in autoimmune and chronic inflammatory diseases. Focusing on Gut-Brain axis he has pioneered research in MS, which is an autoimmune disease of the central nervous system, by demonstrating inflammation and increased permeability in the gut and introduced microbiota-based therapies using combination of probiotic bacteria. He is the founder of ImmuneBiotech Consultancy, ImmuneBiotech AB and ImmuneIntelligence AB in Sweden. He has developed a proprietary lactobacilli library and established accurate and multiple selection technologies to screen and design formulations for the optimal therapeutic management of the diseases. ImmuneBiotech ́s first product, designed to address the underlying causes of Irritable Bowel Syndrome (IBS), has shown major success and will soon be available in the market.

Dr. Barbara Joyce-Shaikh, US

Project Leader, Discovery Research

Merck Research Laboratories

Barbara Joyce-Shaikh completed her B.S. in molecular biology at San Jose State University. She has more than 20 years of biotech industry experience specialising in translational systems of immune function and immune-oncology. Her work has contributed several patents as well as medical literature published in journals such as ‘Nature,’ ‘Immunity,’ ‘Nature Medicine,’ and the ‘Journal of Experimental Medicine.’ She is currently a project leader in the discovery immuno-oncology group at Merck Research Laboratories, Palo Alto, CA, USA (Formerly DNAX Research Institute). Her current research utilises syngeneic and humanised mouse tumour systems to model how immune cells interact with the microbiome and tumour microenvironment with the goal to discover novel immunomodulatory agents and combinatorial treatments to fight resistant cancers.

Dr. Oliver Chao, FR

Head, Emerging Biomedical Sciences Strategy & Innovation

Sanofi

Dr. Chao is head of emerging biomedical sciences/ responsible partner in the strategy & business development unit at Sanofi in France. Dr. Chao is a biochemist/molecular biologist by training, via Univ. of Illinois, Univ. of Chicago, and INSERM/College de France.

Dr. Bram Vanparys, NL

Partner – Health & Care

Gimv

Bram Vanparys, PhD, MBA, joined M Ventures in 2015 as investment director. Between 2010 and 2015, Bram was senior investment manager life sciences at PMV (Brussels, Belgium), where he built the biotech franchise. He was instrumental in the start-up, growth, and exit of several biotech companies. He holds a PhD in biotechnology from the University of Ghent, Belgium and an MBA from Vlerick Business School, Belgium. Bram is based in Amsterdam. He is currently a board member at Calypso (Netherlands), Vaximm (Switzerland), and Explore Bio 1 (Israel) and previously had board positions at Multiplicom, Cartagenia (both acquired by Agilent), and Q-Biologicals (acquired by AmatsiGroup, now Eurofins).

Dr. Hassan Benameur, DE

Senior Director Oral Drug Delivery Innovation, Global Pharma Biotech R&D

Lonza Biologics plc

Hassan Benameur, Ph.D., President of Capsugel France: he joined Capsugel R&D in 2002 and currently leads the Pharmaceutical Sciences department. Dr. Benameur is a Chemical Engineer and holds a PhD in Pharmaceutical Sciences from the Free University of Belgium. He is also a lecturer at several academic and industrial symposia (US, Europe, China, Japan) and was presented the Academy of Pharmaceutical Science and Technology, Japan Award in 2005. Dr. Benameur is a member of several major scientific associations (AAPS, APGI, BCRG, PSTJ and CRS) and scientific academies, and is also the author of 40 scientific publications and the inventor of 20 patents. Prior to joining Capsugel, Dr. Benameur held various positions in Pharmaceutical Research and Development within Therapeutica, SMB Galephar, and Gattefossé.

Dr. Hassan Benameur is Senior Director Oral Drug Delivery Innovation, Global Pharma Biotech R&D at Lonza, with over 20 years of expertise in advanced drug delivery development. Dr. Benameur provides expertise in novel polymer applications for drug delivery and optimized lipid-based formulations for enhanced absorption to maximize.

Dr. Olga Sakwinska, CH

Nestlé Institute of Health Sciences

Nestlé Research Center

Dr. Olga Sakwinska works as a senior scientist at Nestlé Research Center (Nestec SA) in Lausanne, Switzerland. After receiving her PhD from University from Basel, she worked on the pathobiology of human opportunistic pathogen Staphylococcus aureus at the University of Lausanne. She transitioned to Nestlé in 2010. Her current research interests include links between infant health and microbiota of gut and respiratory system; the impact of microbiota on health, in particular, childhood infections, and the potential to modulate microbiota by nutritional interventions.

Dr. Colette Shortt, UK

Former Director, Global Regulatory Affairs Emerging Science & Innovation J&J Consumer Health

J&J Consumer Health

Before joining J&J, Colette Shortt was science director at Yakult (the Japanese pro­biotic company) and held a research nutrition position at SmithKline Beecham Con­sumer Healthcare. Colette has been active in the development of product-related standards and health claim substantiation throughout her career and coordinated one of the most successful disease risk reduction health claim regulatory submissions in Europe while at J&J’s McNeil Nutritionals Ltd. Colette is a registered nutritionist, Fellow of the Association for Nutrition, Fellow of the Royal Society of Medicine and a visiting professor at Ulster University. She is active on the board of the Pharmabiotic Institute and International Life Science Institute. She is a graduate of the National University of Ireland, with post-graduate qualifications in nutrition (MSc, PhD) and business (MBA) from the University of Surrey, UK.

Dr. Kristin Wannerberger, CH

Director Alliance Management R&D

Ferring Pharmaceuticals

Dr. Wannerberger holds a Ph.D. in Biophysical Technology from Lund University, Sweden and a M.Sc. Chem. Eng. - Food and Dairy Technology.
She has worked 17 years in the Pharmaceutical Industry with development of drugs covering various therapeutical areas and several administration forms. Dr Wannerberger has had various positions based in Sweden, Denmark and Switzerland. Dr Wannerberger currently holds a position as Director Alliance Management R&D, based in Switzerland. She is directing several alliances in
the field of the human microbiota/microbiome.

Dr. Audrey Gueniche, FR

Clinical Scientific Coordinator / Senior Expert, Advanced Research

L’Oréal Research & Innovation

Audrey Gueniche obtained her pharmacist degree and her PhD degree in skin biology more than 20 years ago. She has great expertise in immunology and microbiology. Her main expertise is in skin topical treatment and food supplement for skin and hair health, especially using probiotics, natural extract and bacterial extracts. She is currently a clinical expert in L’Oreal Research. She has experience in the actives through formulations/vitro evaluations/ pre-clinical studies to clinical trials. Her passion is to always reinvent evaluation and find new fields of the area in term of actives to promote.

She has published over 100 papers in peer-reviewed journals, 5 chapters in books, and 2 specials issues in a journal where she was the invited editor. She presented at over 70 international congresses and additionally she was personally invited to give more than 30 plenary conferences.

Dr. Jean de Gunzburg, UK

Chief Scientific Officer

Da Volterra

Jean de Gunzburg is a cell and molecular biologist who led an academic career with public institutions in the field of cancer research in France from 1978 to 2005. Trained at the Institut Pasteur inParis (France), and the Whitehead Institute for Biomedical Research (Cambridge, MA, USA), the last position held by Jean in his academic career as director of the signal transduction and oncogenesis laboratory at the Institut Curie in Paris. In 2005 Jean switched from academic research industry and became the chief scientific officer of Da Volterra, a privately held emerging biotechnology company, headquartered in Paris, France. It is committed to the discovery and development of innovative approaches to control the emergence and dissemination of antibiotic resistance, as well as the treatment of specific infectious diseases corresponding to largely unmet medical needs. Da Volterra’s mission is to tackle these worldwide dramatic issues consecutive to the ever-increasing bacterial resistance through the application of its proprietary technologies and products. Jean is the author of over 70 publications in international peer-reviewed scientific journals.

Dr. Gregory Lambert, FR

CEO – VP R&D

TargEDys SA

Grégory Lambert’s career has been split between biotech and pharmaceutical companies, in roles such as VP of R&D and General Manager of Novagali Pharma (now Santen) and CSO at Septodont. His responsibilities covered management of IP and business development activities, innovation and CMC as well as pre-clinical and clinical development in Europe and North America. Gregory is an inventor on more than 20 patents, he was involved in the IPO of Novagali Pharma and he drove the development of several pharmaceutical products from the laboratory to market authorisations. In 2014, Gregory joined the scientific founders of TargEDys as CEO to setup the business plan and start operations.

Dr. Patrice Garnier, FR

Chief Executive Officer

Amabiotics

Dr. Patrice Garnier is chief executive officer for Amabiotics, a biopharmaceutical company that develops innovative diagnostics and microbiome-derived medicines to fight age-related diseases with a strong research focus on gut-brain axis pathologies, metabolic disorders, and oncology. The leading drug candidate, AMA-101, is a potentially first-in-class therapy for Parkinson’s disease.

Dr. Garnier is an entrepreneur with 20 years of experience leading high-tech companies. Prior to joining Amabiotics in 2013, he founded and served for 9 years as CEO in a bioinformatics company that delivers genome to metabolome solutions for data analysis and management. He also co-founded IgenBio (www.igenbio. com) in 1993, a US-based company which develops genome analysis products and services for the life science industry. Dr. Garnier holds an MSc in quantum physics from the École Normale Supérieure in Paris. He completed his PhD in nanotechnology in Professor Catherine Brechignac’s group at the Laboratoire Aimée Cotton, CNRS.

Dr. Ylaine Gerardin, US

Data Scientist

Finch

Dr. Ylaine Gerardin received her PhD in Systems Biology from Harvard University, where her thesis work combined experimental and theoretical methods to understanding the evolution of microbial interactions. Her postdoctoral work at MIT focused on engineering symbiotic host-microbiome relationships. Currently a Data Scientist at Finch, she leads efforts in using machine-learning approaches on high-throughput data towards designing rationally-selected microbial therapeutics.

Dr. Imke Mulder, UK

Research Director

4D Pharma Research Ltd.

Imke Mulder is the Research Director at 4D pharma Research Ltd in Aberdeen, Scotland, where she leads a multidisciplinary research group of 35 scientists. After completing her MSc at Wageningen University in the Netherlands, she moved to Aberdeen in 2001 to pursue her PhD studies at the Department of Zoology, working on the effects of dietary components on the gut immunesystem. Imke then carried out her post-doctoral work as a Research Fellow in the Gut Immunology Group at the Rowett Institute of Nutrition and Health (RINH) in Aberdeen. This work primarily focussed on interactions between the gut microbiota and the host immune system, specifically investigating the cell-specific signaling pathways and effector molecules involved in driving health-promoting interactions of the gut microbiota. Imke moved to 4D pharma Research Ltd in 2014 where she leads the development of the MicroRx platform for the discovery of new live biotherapeutics. MicroRx is able to rapidly interrogate our proprietary library of over 6,500 bacterial isolates for therapeutic functionality by identifying strains which have significant effects on the host and by targeting those diseases which are driven by pathways which match the host-response profile of the strain. Using industry-standard methods, as well as our proprietary disease models, we selectour live biotherapeutics based on their efficacy and ability to be rapidly translated into a drug.

Dr. Gianluca Ianiro, IT

Digestive Disease Center

IRCCS Fondazione Policlinico Universitario ‘A. Gemelli’, Rome

Gianluca Ianiro works as a gastroenterologist at the Fondazione Policlinico “A. Gemelli”, Rome, Italy. He has published more than 90 full papers, mainly on gut microbiota and fecal microbiota transplantation (FMT). He was the secretary of the first European consensus conference on FMT. He is a member of the SIGE (Italian Society of Gastroenterology) governing board, of the UEG (United European Gastroenterology) Research Board and of the UEG Young Talent Group. He was among the course directors of the UEG Basic Science Course on gut microbiota. He is an associate editor of the Human Microbiome Journal (Elsevier).

Dr. Morten L. Isaksen, NO

CEO

Bio-Me

Dr. Isaksen has extensive experience with commercial biotech, and established and run several biotech companies in Norway and in the UK. In addition, he has acted as consultant for many biotech companies over the years. He has been in involved in the microbiome field for more than a decade. His passion and field of expertise is in developing better assays for gut microbiome analysis. This led him to set up and act as the CEO of Genetic Analysis from 2008 to 2013. Based on the experience and insights from that venture, he set up and is the CEO of Bio-Me in 2016. Bio-Me offers next generation gut microbiome analysis, making it possible to analyze hundreds of fecal samples in less than a day, with high resolution and low cost.

Dr. Frédéric Baribaud, US

Scientific Director

Janssen R&D

Dr. Shahram Lavasani, SE

Founder & CEO

ImmuneBiotech AB

Dr. Barbara Joyce-Shaikh, US

Project Leader, Discovery Research

Merck Research Laboratories

Dr. Oliver Chao, FR

Head, Emerging Biomedical Sciences Strategy & Innovation

Sanofi

Dr. Bram Vanparys, NL

Partner – Health & Care

Gimv

Dr. Hassan Benameur, DE

Senior Director Oral Drug Delivery Innovation, Global Pharma Biotech R&D

Lonza Biologics plc

Dr. Olga Sakwinska, CH

Nestlé Institute of Health Sciences

Nestlé Research Center

Dr. Colette Shortt, UK

Former Director, Global Regulatory Affairs Emerging Science & Innovation J&J Consumer Health

J&J Consumer Health

Dr. Kristin Wannerberger, CH

Director Alliance Management R&D

Ferring Pharmaceuticals

Dr. Audrey Gueniche, FR

Clinical Scientific Coordinator / Senior Expert, Advanced Research

L’Oréal Research & Innovation

Dr. Jean de Gunzburg, UK

Chief Scientific Officer

Da Volterra

Dr. Gregory Lambert, FR

CEO – VP R&D

TargEDys SA

Dr. Patrice Garnier, FR

Chief Executive Officer

Amabiotics

Dr. Ylaine Gerardin, US

Data Scientist

Finch

Dr. Imke Mulder, UK

Research Director

4D Pharma Research Ltd.

Dr. Gianluca Ianiro, IT

Digestive Disease Center

IRCCS Fondazione Policlinico Universitario ‘A. Gemelli’, Rome

Dr. Morten L. Isaksen, NO

CEO

Bio-Me

Sponsors